Background: Approximately 35–40% of patients with chronic urticaria have an IgG autoantibody to the IgE receptor which can activate basophils and mast cells so that they release histamine. In this study we assessed the cytokine profile present in chronic urticaria sera, and then measured cytokine and leukotriene release from basophils and mast cells upon incubation with chronic urticaria sera. Finally we assessed cytokine expression at the single-cell level and characterized the T cell subpopulations involved in their production. We chose IL-4 as representative of Th2 lymphocytes and IFN-γ for Th1 lymphocytes. Methods: We analyzed IL-4, IL-5 and IFN-γ in 60 chronic urticaria sera versus 51 controls. Sera were incubated with purified human basophils and cutaneous mast cells and the release of histamine, IL-4 and leukotrienes (C4, D4, E4) was quantitated. Immunoblotting was performed to identify IgG antibody to FcΕRIα, α subunit. We measured intracellular cytokine production in peripheral blood mononuclear cells of 17 chronic urticaria patients compared to 50 healthy controls. Results: We found higher IL-4 levels (p = 0.028) in the sera of chronic urticaria patients (1.03 pg/ml) versus healthy donors (0.20 pg/ml) but no difference between urticaria sera and atopic control sera (0.52 pg/ml). We did not detect IFN-γ or IL-5 in any serum. However, sera that activated basophils so that they released histamine also produced leukotriene and IL-4, and leukotriene production by cutaneous mast cells and basophils was closely correlated. However, there was no correlation between immunoblotting and the functional ability to induce either histamine or IL-4. After stimulating with PMA-ionomycin we found significant differences in CD4+ lymphocyte production of IL-4 and IFN-γ with no differences in CD8+ lymphocyte production of either cytokine. Conclusion: Our data support the presence of basophil and mast cell activators in the sera of patients with chronic urticaria which can lead to the production of leukotrienes and IL-4 in addition to the histamine. IL-4 levels are similar to those seen in atopic subjects. We found that CD4+ T cells from patients with chronic urticaria are activated and tend to produce higher cytokine levels than CD4+ T cells from healthy controls. There were no differences when cytokine production by CD8+ lymphocytes was similarly assessed. These results are consistent with the histology found in biopsies of chronic urticaria lesions, where a CD4+-predominant infiltrate is found with cytokine production suggesting either a Th0 response or a mixture of Th1 and Th2 lymphocytes.

Keywords:
Basophil, Cytokines, Histamine, IL-4, Urticaria, Mast cell, Leukotriene
1.
Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599–1604.
2.
Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschlager M, Kinet JP, Stingl G: Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: A selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995;96:2606–2612.
3.
Ferrer M, Kinét J-P, Kaplan A: Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha subunit) in chronic urticaria. J Allergy Clin Immunol 1998;101:672–676.
4.
Grattan CE, Francis DM, Hide M, Greaves MW: Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695–704.
5.
Niimi N, Francis DM, Kermani F, O’Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996;106:1001–1006.
6.
Kikuchi Y, Kaplan AP: A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002;109:114–118.
7.
Fiebiger E, Hammerschmid F, Stingl G, Maurer D: Anti-fcepsilon RIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998;101:243–251.
8.
Ferrer M, Nakazawa K, Kaplan AP: Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999;104:169–172.
9.
O’Donnell BF, O’Neill CM, Francis DM, Niimi N, Barr RM, Barlow RJ, Kobza Black A, Welsh KI, Greaves MW: Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999;140:853–858.
10.
Openshaw P, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K, A OG: Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995;182:1357–1367.
11.
Benyon RC, Church MK, Clegg LS, Holgate ST: Dispersion and characterisation of mast cells from human skin. Int Arch Allergy Appl Immunol 1986;79:332–334.
12.
Rein G, Karasek MA: Factors affecting the growth and maintenance of human skin mast cells in cell culture. Int Arch Allergy Immunol 1992;98:211–219.
13.
Grattan CE, Walpole D, Francis DM, Niimi N, Dootson G, Edler S, Corbett MF, Barr RM: Flow cytometric analysis of basophil numbers in chronic urticaria: Basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997;27:1417–1424.
14.
Plaut M, Kazimierczak W, Lichtenstein LM: Abnormalities of basophil ‘releasability’ in atopic and asthmatic individuals. J Allergy Clin Immunol 1986;78:968–973.
15.
Natbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP: Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983;71:177–183.
16.
Haas N, Toppe E, Henz BM: Microscopic morphology of different types of urticaria. Arch Dermatol 1998;134:41–46.
17.
Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, Black MM, Black AK, Greaves MW: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999;103:484–493.
18.
Del Prete G, De Carli M, Almerigogna F, Daniel CK, D’Elios MM, Zancuoghi G, Vinante F, Pizzolo G, Romagnani S: Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:81–86.
19.
Schroeder JT, Lichtenstein LM, Roche EM, Xiao H, Liu MC: IL-4 production by human basophils found in the lung following segmental allergen challenge. J Allergy Clin Immunol 2001;107:265–271.
20.
Devouassoux G, Foster B, Scott LM, Metcalfe DD, Prussin C: Frequency and characterization of antigen-specific IL-4- and IL-13-producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. J Allergy Clin Immunol 1999;104:811–819.
21.
Austen KF, Boyce JA: Mast cell lineage development and phenotypic regulation. Leuk Res 2001;25:511–518.
22.
Kikuchi Y, Kaplan AP: Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001;107:1056–1062.
23.
el-Lati SG, Dahinden CA, Church MK: Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994;102:803–806.
24.
Fureder W, Agis H, Speer WR, Lechner K, Valent P: The surface membrane antigen phenotype of human blood basophils. Allergy 1994;49:861–865.
25.
Barlow RJ, Ross EL, MacDonald DM, Kobza BA, Greaves MW: Mast cells and T lymphocytes in chronic urticaria. Clin Exp Allergy 1995;25:317–322.
26.
Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002;109:694–700.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.